Expanding Manufacturing Capacity ProBioGen AG has recently expanded its manufacturing capacity with the addition of a new building housing 1000 L single-use bioreactor capacity. This expansion positions the company to cater to the increasing demand from clients, presenting a sales opportunity to engage with biotech and pharma companies looking for CDMO and manufacturing services.

Strategic Partnerships Through recent partnerships with ModeX Therapeutics Inc, Diosvax, Mapp Bio, and GeoVax, ProBioGen AG has showcased its collaborative approach in the biopharmaceutical industry. These collaborations open up avenues for sales representatives to explore synergies with partners and potentially attract new clients seeking innovative solutions offered by ProBioGen.

Proprietary Technologies ProBioGen offers proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis, including the DirectedLuck transposase system and GlymaxX technology. Highlighting these cutting-edge technologies in sales pitches can differentiate the company from competitors and appeal to organizations aiming to enhance antibody development and cellular cytotoxicity.

Market Leadership in LV Production With the launch of the platinum standard lentivirus (LV) packaging cell line Lenti.RiGHT™, ProBioGen AG has solidified its position as a leader in LV production. Leveraging this achievement in sales conversations can attract clients seeking high-quality LV production services, presenting an opportunity to position ProBioGen as a preferred partner in viral vector manufacturing.

Experienced Team and Intellectual Property ProBioGen's 30 years of experience in animal cell culture, combined with a strong intellectual property base, positions the company as a reliable and knowledgeable partner in biopharmaceutical development. Sales professionals can leverage this expertise to build credibility with potential clients seeking established CDMOs with a proven track record of successful projects.